Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Other solid neoplasm 3Gynecologic 2Gastrointestinal 2Breast 1

Conditions

Leukemia, Myeloid, Acute 97Precursor Cell Lymphoblastic Leukemia-Lymphoma 61Myelodysplastic Syndromes 52Recurrence 37Leukemia, Lymphocytic, Chronic, B-Cell 37Multiple Myeloma 36Lymphoma, Non-Hodgkin 35Lymphoma 34Lymphoma, B-Cell 29Hematologic Neoplasms 28Lymphoma, Follicular 24Lymphoma, Large B-Cell, Diffuse 23Melanoma 22Lymphoma, Mantle-Cell 22Leukemia 22Lymphoma, B-Cell, Marginal Zone 20Myeloproliferative Disorders 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 19Leukemia, Biphenotypic, Acute 18Hodgkin Disease 18Ovarian Neoplasms 17Burkitt Lymphoma 17Pancreatic Neoplasms 16Neoplasms 13Neoplasm Metastasis 12Leukemia, Myelomonocytic, Chronic 12Colorectal Neoplasms 11Anemia, Refractory, with Excess of Blasts 11Stomach Neoplasms 10Carcinoma, Non-Small-Cell Lung 10

Interventions

Cisplatin 15Pemetrexed 12pembrolizumab 9Carboplatin 8Nivolumab 7Cyclophosphamide 6Platinum 5Ipilimumab 51,2-diaminocyclohexaneplatinum II citrate 5fludarabine 3Radiotherapy, Intensity-Modulated 3Interleukin-2 3Gemcitabine 3tremelimumab 2durvalumab 2atezolizumab 2aldesleukin 2Radiotherapy 2Radiation 2Photochemotherapy 2Pharmaceutical Preparations 2Methotrexate 2Drug Therapy 2Chemotherapy, Adjuvant 2Cerebral Decortication 2nintedanib 1methoxyamine 1decitabine and cedazuridine drug combination 1cemiplimab 1cediranib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × fludarabine × 1 year × Clear all
NCT07510815 2026-04-06

DUAL-MESO-NK

Beijing Biotech

Phase 1/2 Recruiting
36 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
57 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
6 enrolled
BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡